Org 28611

Org 28611 is a chemical compound that belongs to the class of benzodiazepine drugs. It is a psychoactive drug that has been studied for its potential therapeutic uses in the treatment of various neurological disorders and mental health conditions.

History

Org 28611 was first synthesized in the late 20th century by Organon International, a pharmaceutical company based in the Netherlands. The compound was developed as part of Organon's research into new benzodiazepine derivatives with potential therapeutic applications.

Pharmacology

Like other benzodiazepines, Org 28611 acts on the GABA receptor, a type of neurotransmitter receptor in the brain. It enhances the effect of the neurotransmitter GABA, which is involved in regulating neuronal excitability and has a calming effect on the nervous system.

Therapeutic Potential

Org 28611 has been studied for its potential use in the treatment of conditions such as anxiety disorders, insomnia, and seizure disorders. However, as of the present time, it has not been approved for medical use by any regulatory authority.

Side Effects and Risks

As with other benzodiazepines, the use of Org 28611 carries the risk of side effects such as drowsiness, dizziness, and dependency. Long-term use can lead to tolerance, withdrawal symptoms, and benzodiazepine withdrawal syndrome.

See Also

• Benzodiazepine
• GABA receptor
• Organon International

References

<references />

This article is a stub related to chemistry. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!